AYTU BIOPHARMA, INC Goodwill & Intangibles Disclosure

Note 7 - Intangible Assets

 

A summary of the Company’s intangible assets as of June 30, 2024, and June 30, 2023, is as follows:

 

​		June 30, 2024
​		Gross Carrying Amount				Accumulated Amortization				Net Carrying Amount				Weighted-Average Remaining Life
​		(in thousands)												(in years)
Acquired product technology rights		$	41,268			$	(13,184	)		$	28,084				10.5
Acquired technology rights			30,200				(5,831	)			24,369				13.8
Total definite-lived intangible assets		$	71,468			$	(19,015	)		$	52,453				12.0

 

​		June 30, 2023
​		Gross Carrying Amount				Accumulated Amortization				Net Carrying Amount				Weighted-Average Remaining Life
​		(in thousands)												(in years)
Acquired product technology rights		$	42,176			$	(10,881	)		$	31,295				11.5
Acquired technology rights			30,200				(4,054	)			26,146				14.8
Acquired product distribution rights			6,207				(4,678	)			1,529				1.0
Total definite-lived intangible assets		$	78,583			$	(19,613	)		$	58,970				12.7

 

Gross carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $6.5 million and $6.1 million for the years ended June 30, 2024, and 2023, respectively.

 

The following table summarizes the estimated future amortization expense of intangible assets to be recognized over the next five years and periods thereafter:

 

​		June 30,
​		(in thousands)
2025		$	4,989
2026			4,989
2027			4,989
2028			4,989
2029			4,989
Thereafter			27,508
Total future amortization expense		$	52,453

 ​

Acquired Product Technology Rights

 

The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisition of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021.

 

Karbinal

 

The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August of 2033, with an optional initial 20-year extension.

 

Poly-Vi-Flor and Tri-Vi-Flor

 

The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.

 

ADHD Portfolio

 

As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 16 years.

 

Acquired Technology Right

 

TRRP Proprietary Technology

 

As part of the Neos Acquisition, the Company acquired time release resin particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well.

 

Acquired Product Distribution Rights

 

In connection with the acquisition of Innovus Pharmaceuticals, Inc. (“Innovus”) in February 2020 (the “Innovus Acquisition”), the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the fiscal year ended June 30, 2023, this intangible asset was impaired by $3.0 million due to the discontinuance of products in the Consumer Health Segment. As of June 30, 2024, this intangible asset was fully amortized and removed from gross carrying value.

 

Acquired In-Process R&D

 

IPR&D – NT0502

 

As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity that was being developed for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended June 30, 2023, the Company terminated its development program of NT0502. As a result, the Company fully impaired the IPR&D of NT0502, recording impairment expense of $2.6 million to its Rx Segment during the second quarter of fiscal 2023.